Cargando…
Serum ATX as a novel biomarker for breast cancer
Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456097/ https://www.ncbi.nlm.nih.gov/pubmed/30921203 http://dx.doi.org/10.1097/MD.0000000000014973 |
_version_ | 1783409704907571200 |
---|---|
author | Shao, Yingbo Yu, Yang He, Yaning Chen, Qi Liu, Hui |
author_facet | Shao, Yingbo Yu, Yang He, Yaning Chen, Qi Liu, Hui |
author_sort | Shao, Yingbo |
collection | PubMed |
description | Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations of serum autotaxin in breast cancer and discuss whether serum autotaxin could be useful as a novel parameter of breast cancer. Serum autotaxin antigen was measured in 112 patients with breast cancer and 50 healthy volunteers by ELISA. The association of serum autotaxin antigen levels with clinicopathological parameters and outcomes of breast cancer was analyzed. Serum autotaxin antigen was significantly higher in breast cancer patients than healthy volunteers (291.32 ± 38.02 ng/ml vs 254.04 ± 21.03 ng/ml, respectively; P < .0001). Serum autotaxin measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.798, 95% CI: 0.732–0.864) with an optimal cut-off value of 267.34 ng/ml (sensitivity = 0.741, specificity = 0.800). Increased serum autotaxin was associated with breast cancer nodal status (P = .007), Tumor-Node- Metastasis (TNM) stage (P = .009) and Ki-67 index (P = .004). Univariate and multivariate Cox regression analysis revealed that elevated serum autotaxin showed an independent prognostic value for poor Disease-free survival. Our present study confirmed the elevation, potential diagnostic, and independent prognostic value of serum autotaxin for breast cancer. Serum autotaxin could serve as a reliable novel biomarker for breast cancer. |
format | Online Article Text |
id | pubmed-6456097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-64560972019-05-29 Serum ATX as a novel biomarker for breast cancer Shao, Yingbo Yu, Yang He, Yaning Chen, Qi Liu, Hui Medicine (Baltimore) Research Article Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations of serum autotaxin in breast cancer and discuss whether serum autotaxin could be useful as a novel parameter of breast cancer. Serum autotaxin antigen was measured in 112 patients with breast cancer and 50 healthy volunteers by ELISA. The association of serum autotaxin antigen levels with clinicopathological parameters and outcomes of breast cancer was analyzed. Serum autotaxin antigen was significantly higher in breast cancer patients than healthy volunteers (291.32 ± 38.02 ng/ml vs 254.04 ± 21.03 ng/ml, respectively; P < .0001). Serum autotaxin measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.798, 95% CI: 0.732–0.864) with an optimal cut-off value of 267.34 ng/ml (sensitivity = 0.741, specificity = 0.800). Increased serum autotaxin was associated with breast cancer nodal status (P = .007), Tumor-Node- Metastasis (TNM) stage (P = .009) and Ki-67 index (P = .004). Univariate and multivariate Cox regression analysis revealed that elevated serum autotaxin showed an independent prognostic value for poor Disease-free survival. Our present study confirmed the elevation, potential diagnostic, and independent prognostic value of serum autotaxin for breast cancer. Serum autotaxin could serve as a reliable novel biomarker for breast cancer. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6456097/ /pubmed/30921203 http://dx.doi.org/10.1097/MD.0000000000014973 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Shao, Yingbo Yu, Yang He, Yaning Chen, Qi Liu, Hui Serum ATX as a novel biomarker for breast cancer |
title | Serum ATX as a novel biomarker for breast cancer |
title_full | Serum ATX as a novel biomarker for breast cancer |
title_fullStr | Serum ATX as a novel biomarker for breast cancer |
title_full_unstemmed | Serum ATX as a novel biomarker for breast cancer |
title_short | Serum ATX as a novel biomarker for breast cancer |
title_sort | serum atx as a novel biomarker for breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456097/ https://www.ncbi.nlm.nih.gov/pubmed/30921203 http://dx.doi.org/10.1097/MD.0000000000014973 |
work_keys_str_mv | AT shaoyingbo serumatxasanovelbiomarkerforbreastcancer AT yuyang serumatxasanovelbiomarkerforbreastcancer AT heyaning serumatxasanovelbiomarkerforbreastcancer AT chenqi serumatxasanovelbiomarkerforbreastcancer AT liuhui serumatxasanovelbiomarkerforbreastcancer |